APOC3 and chronic kidney disease: Our findings demonstrate a statistically significant association between baseline apoC-III levels and eGFR decline that was attenuated only partly after adjusting for known risk factors of CKD progression including hemoglobin A1c, a confounder in both CKD progression and in the lipid metabolism pathway as hyperglycemia drives TG and VLDL production [10].